Maria Palasis
CIK: 0001810701
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- May 21, 2026BBNX
Beta Bionics, Inc.
Award(A)Direct17K shares- - Apr 1, 2026LYRA
Lyra Therapeutics, Inc.
Disposition(D)Direct2K shares- - Jan 13, 2026BBNX
Beta Bionics, Inc.
Award(A)Direct4K shares- - Jan 6, 2026LYRA
Lyra Therapeutics, Inc.
Sale(S)Direct1.7K shares at avg. $3.36$6K - Dec 1, 2025BBNX
Beta Bionics, Inc.
Sale(S)Direct906 shares at avg. $29.33$27K - Dec 1, 2025BBNX
Beta Bionics, Inc.
Sale(S)Direct500 shares at avg. $29.96$15K - Oct 31, 2025BBNX
Beta Bionics, Inc.
Sale(S)Direct1.3K shares at avg. $26.86$35K - Oct 31, 2025BBNX
Beta Bionics, Inc.
Sale(S)Direct119 shares at avg. $27.45$3K - Oct 1, 2025LYRA
Lyra Therapeutics, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
3.7K shares- - Jul 10, 2025LYRA
Lyra Therapeutics, Inc.
Sale(S)Direct1.6K shares at avg. $8.91$14K - Mar 15, 2025BBNX
Beta Bionics, Inc.
Award(A)Direct11.2K shares- - Jan 31, 2025BBNX
Beta Bionics, Inc.
Award(A)DirectDirector Stock Option (right to buy)
9.1K shares- - Jan 8, 2025LYRA
Lyra Therapeutics, Inc.
Award(A)Direct800K shares- - Dec 9, 2024LYRA
Lyra Therapeutics, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
183.3K shares- - Oct 16, 2024LYRA
Lyra Therapeutics, Inc.
Award(A)Direct300K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 21, 2026 |  BBNX Beta Bionics, Inc. | Award(A) | 16,965 | - | $0 | Direct |
| Apr 1, 2026 |  LYRA Lyra Therapeutics, Inc. | Disposition(D) | 2,000 | - | $0 | Direct |
| Jan 13, 2026 | BBNX Beta Bionics, Inc. | Award(A) | 3,997 | - | $0 | Direct |
| Jan 6, 2026 | LYRA Lyra Therapeutics, Inc. | Sale(S) | 1,702 | $3.36 | $5,726 | Direct |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | Sale(S) | 906 | $29.33 | $26,570 | Direct |
| Dec 1, 2025 | BBNX Beta Bionics, Inc. | Sale(S) | 500 | $29.96 | $14,982 | Direct |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | Sale(S) | 1,287 | $26.86 | $34,567 | Direct |
| Oct 31, 2025 | BBNX Beta Bionics, Inc. | Sale(S) | 119 | $27.45 | $3,267 | Direct |
| Oct 1, 2025 | LYRA Lyra Therapeutics, Inc. | Award(A) Employee Stock Option (right to buy) | 3,667 | - | - | Direct |
| Jul 10, 2025 | LYRA Lyra Therapeutics, Inc. | Sale(S) | 1,565 | $8.91 | $13,944 | Direct |
| Mar 15, 2025 | BBNX Beta Bionics, Inc. | Award(A) | 11,247 | - | - | Direct |
| Jan 31, 2025 | BBNX Beta Bionics, Inc. | Award(A) Director Stock Option (right to buy) | 9,137 | - | - | Direct |
| Jan 8, 2025 | LYRA Lyra Therapeutics, Inc. | Award(A) | 800,000 | - | $0 | Direct |
| Dec 9, 2024 | LYRA Lyra Therapeutics, Inc. | Award(A) Employee Stock Option (right to buy) | 183,333 | - | - | Direct |
| Oct 16, 2024 | LYRA Lyra Therapeutics, Inc. | Award(A) | 300,000 | - | $0 | Direct |
1-15 of 15 transactions
About Palasis Maria
Palasis Maria (SEC CIK 0001810701) files insider reports with the SEC as Director of Beta Bionics, Inc. (BBNX) and Principal Executive Officer of Lyra Therapeutics, Inc. (LYRA).
Signal8 holds 15 ownership filings by Palasis Maria (1 Form 3, 14 Form 4), filed between Oct 18, 2024 and May 26, 2026. Those filings report 15 transactions, from Oct 16, 2024 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Palasis Maria's filings is in WATERTOWN, MA.
Recent filings by Palasis Maria
- May 21, 2026: Grant or award of BBNX shares (Form 4, code A).
- Apr 1, 2026: Disposition to issuer transaction of LYRA shares (Form 4, code D).
- Jan 13, 2026: Grant or award of BBNX shares (Form 4, code A).
- Jan 6, 2026: Open-market sale of LYRA shares (Form 4, code S).
- Dec 1, 2025: Open-market sales of BBNX shares (2 lines, Form 4, code S).
Other insiders filing for Beta Bionics, Inc. (BBNX)
- Mensinger Mike, Chief Product Officer
- Hopman Mark, Chief Commercial Officer
- Jones Christy, Director
- Saint Sean, President & CEO
- Russell Steven Jon, Chief Medical Officer
- Feider Stephen, Chief Financial Officer